Xeljanz
Generic name: tofacitinib
Manufactured by: Pfizer
Therapeutic category: Immunology
Tariff Status Explanation
No exemption or deal has been identified for this drug. It is subject to the full 100% Section 232 tariff on its manufacturer cost basis.
Key Dates
Sept 29, 2026
Section 232 tariff effective for all other companies
April 2, 2030
Onshoring plan exemptions expire (revert to 100%)
What Can You Do?
- →Ask your doctor if a generic or biosimilar equivalent is available. Generics are fully exempt from all tariffs.
- →Check if your manufacturer has signed an MFN deal. View all MFN deals →
- →Use our Savings Guide to find discount programs, patient assistance, and alternatives before tariffs take effect.
Will Xeljanz Cost More Due to Tariffs?
Xeljanz (tofacitinib) is manufactured by Pfizer and is classified as a immunology medication. Based on available information, Pfizer has not signed an MFN deal or identified an approved country-of-manufacture exemption for this drug. This means Xeljanz may be subject to the full 100% Section 232 tariff on its acquisition cost basis, effective September 29, 2026.
Remember that the tariff applies to the drug's acquisition cost — the price pharmacies pay to purchase the drug — not necessarily your final copay. Patients with insurance may see the tariff impact appear gradually through formulary changes or premium increases. Uninsured patients and those paying cash prices may see more direct impacts.